Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
57 stopped studies mapped to Skin Carcinoma and descendants · 98% state a reason
Over the 57 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02321982 | Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery | N/A | withdrawn | Dec 22, 2014 | Dartmouth-Hitchcock Medical Center | Study topic is no longer being pursued by study team members | Other (stated, no rule matched) |
| NCT01808950 | Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular… | Phase 1 / Phase 2 | terminated | Mar 11, 2013 | Spirig Pharma Ltd. | safety issues | Safety / toxicity |
| NCT02507076 | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma… | N/A | withdrawn | Jul 23, 2015 | Albert Einstein College of Medicine | no enrollment | Enrollment / accrual |
| NCT00994240 | Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC | N/A | terminated | Oct 14, 2009 | University of Wisconsin, Madison | slow enrollment, lack of funding | Enrollment / accrual |
| NCT01465815 | Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous… | Phase 1 / Phase 2 | withdrawn | Nov 7, 2011 | OHSU Knight Cancer Institute | Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and OSI-906… | Safety / toxicity |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | Phase 1 | terminated | Mar 26, 2004 | Yale University | not stated | Not stated |
| NCT02080962 | Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer | Phase 2 | terminated | Mar 7, 2014 | Barretos Cancer Hospital | Low rate of recruitment. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 6, 2017source: clinicaltrials